Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Smoking, Acute Coronary Syndrome

In brief

Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Key facts

Study ID

NCT01170338

Run by

Newark Beth Israel Medical Center

People needed

100

Starts

2008-01-01

Last updated by the study team

2010-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• active smokers presenting to hospital with an acute coronary syndrome

You may not qualify if…

• patients with an acute coronary syndrome who are not active smokers

Where it is running

• Newark Beth Israel Medical Center — Newark, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.